Vicky Makker, MD

Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib (Lenvima) and pembrolizumab (Keytruda), in patients with endometrial cancers.

While lenvatinib has previously been approved for the treatment of radioactive iodinerefractory differentiated thyroid cancer, as well as in advanced renal cell carcinoma in combination with everolimus (Afinitor), this agent has shown a modest response rate of 14% in patients with heavily pretreated endometrial cancer.

Videos

Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib and pembrolizumab, in patients with endometrial cancers.

Vicky Makker, MD | Authors

Articles

Modest Response Rates in Endometrial Cancers